Lee Ainslie Maverick Capital
Lee Ainslie is the founder of Maverick Capital, a long/short equity firm that emerged from the Tiger Management network of investors. Maverick is known for fundamental research, sector specialization among teams, and a classic hedge fund long/short structure. Ainslie’s firm remains a reference name among so-called Tiger Cub managers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$121M |
| 2 |
Workday
WDAY
|
+$100M |
| 3 |
Lam Research
LRCX
|
+$60M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$54.1M |
| 5 |
Sea Limited
SE
|
+$52.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$201M |
| 2 |
Alibaba
BABA
|
+$102M |
| 3 |
Meta Platforms (Facebook)
META
|
+$56.4M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$54.2M |
| 5 |
Aon
AON
|
+$51.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 40.52% |
| 2 | Healthcare | 15.55% |
| 3 | Technology | 14.19% |
| 4 | Communication Services | 7.61% |
| 5 | Financials | 5.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Bio-Rad Laboratories Class A
BIO
$10.2B
| – | – |
-273
| Closed | -$176K |
|
652
Blackrock
BLK
$179B
| – | – |
-1,311
| Closed | -$1.15M |
|
653
Cable One
CABO
$129M
| – | – |
-90
| Closed | -$172K |
|
654
Cboe Global Markets
CBOE
$31.4B
| – | – |
-1,149
| Closed | -$137K |
|
655
CBRE Group
CBRE
$44B
| – | – |
-4,945
| Closed | -$424K |
|
656
Commerce Bancshares
CBSH
$8.37B
| – | – |
-2,308
| Closed | -$135K |
|
657
Coca-Cola Europacific Partners
CCEP
$47.7B
| – | – |
-3,647
| Closed | -$216K |
|
658
CDW
CDW
$17.2B
| – | – |
-280
| Closed | -$49K |
|
659
Cullen/Frost Bankers
CFR
$10.2B
| – | – |
-2,550
| Closed | -$286K |
|
660
C.H. Robinson
CHRW
$16.5B
| – | – |
-1,777
| Closed | -$166K |
|
|
CHX
661
DELISTED
ChampionX
CHX
| – | – |
-2,882
| Closed | -$74K |
|
662
Clorox
CLX
$12.9B
| – | – |
-5,399
| Closed | -$971K |
|
663
Comcast
CMCSA
$95.3B
| – | – |
-47,463
| Closed | -$2.71M |
|
664
CME Group
CME
$98.9B
| – | – |
-4,285
| Closed | -$911K |
|
665
CNX Resources
CNX
$5.38B
| – | – |
-8,393
| Closed | -$115K |
|
666
Coherent
COHR
$56.7B
| – | – |
-8,033
| Closed | -$583K |
|
667
Cohu
COHU
$2.57B
| – | – |
-1,054
| Closed | -$39K |
|
668
Collegium Pharmaceutical
COLL
$840M
| – | – |
-33,751
| Closed | -$798K |
|
669
Compass
COMP
$9.02B
| – | – |
-8,702
| Closed | -$114K |
|
670
Coty
COTY
$2.41B
| – | – |
-11,199
| Closed | -$105K |
|
|
CPRX
671
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-35,869
| Closed | -$206K |
|
672
CRH
CRH
$63.2B
| – | – |
-2,496
| Closed | -$127K |
|
673
Charles River Laboratories
CRL
$14.1B
| – | – |
-1,536
| Closed | -$568K |
|
674
Crocs
CROX
$5.85B
| – | – |
-12,018
| Closed | -$1.4M |
|
675
Carlisle Companies
CSL
$14.6B
| – | – |
-940
| Closed | -$180K |
|
Similar funds
Lee Ainslie's Q3 2021 Portfolio in Review
As of Q3 2021, Lee Ainslie held 869 positions worth $9.92B, down 6.9% from $10.6B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Lee Ainslie deployed $866M of net new capital in Q3 2021, opening 208 new positions and adding to 234 existing holdings. Its largest new stake was Instructure Holdings, Inc.: 1,250,000 shares worth $28.2M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 41% of assets, down from 53% a quarter earlier, followed by Healthcare and Technology.
On the sell side, the largest reduction was Coupang, an estimated $201M trimmed.
- Lee Ainslie's largest Q3 2021 buy was Instructure Holdings, Inc.: 1,250,000 shares worth $28.2M.
- Lee Ainslie added most to Visa in Q3 2021, an estimated $121M increase.
- Lee Ainslie's biggest Q3 2021 reduction was Coupang, cutting an estimated $201M.
- Lee Ainslie fully exited Alibaba in Q3 2021, selling an estimated $102M.
- Lee Ainslie's ten largest holdings make up 52% of its $9.92B portfolio in Q3 2021.
- Lee Ainslie opened 208 new positions and closed 244 in Q3 2021.
- Lee Ainslie's portfolio value fell 6.9% quarter-over-quarter to $9.92B.
Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.